T1	Participants 121 161	patients with superficial bladder tumors
T2	Participants 278 307	superficial bladder carcinoma
T3	Participants 568 580	301 patients
T4	Participants 1025 1109	191 patients with superficial bladder carcinoma were available for efficacy analysis
